Diabetes mellitus can cause serious foot problems as a result of diabetic neuropathy (loss of normal nerve function) and peripheral vascular disease (loss of normal circulation). These two conditions can lead to diabetic foot ulcers, as the nerves that usually carry pain sensation to the brain from the feet do not function as well and it is possible for unintentional foot damage to occur. Wearing tight shoes, cuts, blisters and bruises can all develop into diabetes foot ulcers. In a person with diabetes, a foot ulcer is defined as a patch of broken skin usually on the lower leg or feet. Diabetic foot ulcers can affect people with both type 1 and type 2 diabetes.
When blood sugar levels are high or fluctuate regularly, as in people with diabetes, skin that would normally heal may not properly repair itself because of nerve damage. As a result, even a mild injury can start a foot ulcer. Granexin gel contains the peptide ACT1, which possesses potential anti-inflammatory and regenerative properties when administered topically to diabetic foot ulcers. If licensed, granexin gel may offer an additional therapy option for diabetic foot ulcers which are a particularly difficult-to-treat chronic wound type.
The Visualase™ system, developed by Medtronic plc, is indicated to necrotize or coagulate soft tissue through interstitial thermal therapy under MRI guidance. The Visualase™ system comprises a cooled laser applicator and a working station containing a peristaltic pump for circulating coolant (saline) through the applicator, a diode laser energy source and a computer with MRI analysis software …